SGLT2 inhibitors reduce ventricular arrhythmias and sudden cardiac death in heart failure patients, with benefits persisting in long-term follow-up. Future trials are needed to confirm these cardioprotective effects.
Enhancing clinical service design for multimorbidity management: A comprehensive approach to joined-up care for diabetes, chronic kidney disease, and heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38978167/
A CKM service has the potential to increase the uptake of cardiac and renal protective medications as well as optimising metabolic care, increase capacity in both primary and secondary care,...
Multimorbidity challenges holistic care delivery, especially in CKM syndrome. Integrated, patient-centered care with interdisciplinary teams, telehealth, and policy reforms can optimize outcomes, enhance access, and improve quality of life for patients.
Need for a Cardiogenic Shock Team Collaborative-Promoting a Team-Based Model of Care to Improve Outcomes and Identify Best Practices - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38456417/
Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. It is a time-sensitive condition...
Cardiogenic shock teams, modeled after the Pulmonary Embolism Response Team Consortium, aim to enhance outcomes through multidisciplinary collaboration, shared protocols, education, and process improvement to address high mortality and resource challenges.
State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38848447/
Pulsed field ablation (PFA) is an innovative approach in the field of cardiac electrophysiology aimed at treating cardiac arrhythmias. Unlike traditional catheter ablation energies, which use radiofrequency or cryothermal energy...
Pulsed field ablation (PFA) uses electroporation for precise cardiac arrhythmia treatment, offering advantages like reduced thermal damage and improved outcomes, revolutionizing catheter ablation with evolving technology and clinical applications.
Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association: Endorsed by the Pediatric & Congenital Electrophysiology Society (PACES) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38314551/
Disorders of the cardiac rhythm may occur in both the fetus and neonate. Because of the immature myocardium, the hemodynamic consequences of either bradyarrhythmias or tachyarrhythmias may be far more...
This statement reviews fetal and neonatal arrhythmias, their mechanisms, pharmacological treatments, unique pharmacokinetics, hemodynamic impacts, and highlights research gaps and long-term developmental consequences of interventions and antiarrhythmic medications.